To include your compound in the COVID-19 Resource Center, submit it here.

GPI 1485 neuroimmunophilin ligand: Phase II

GLFD began a double-blind, placebo-controlled Phase II in 200 patients

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE